Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
07
2019
accepted:
12
11
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
26
3
2020
Statut:
epublish
Résumé
Standardized Ginkgo biloba extract (GBE) has demonstrated efficacy in the cognitive functional neuropsychiatric symptoms of patients with Alzheimer's disease (AD). With regard to its underlying molecular mode of action, first evidence was provided that GBE was able to modulate neuronal outgrowth in vitro, but the mechanisms underlying GBE effects on neuroplasticity remain unclear. In this study, we investigated the effect of GBE on neurite outgrowth using SH-SY5Y neuroblastoma cells in a 2D and 3D surface culture. The effects of the GBE LI1370 on neuroplasticity and neurite outgrowth were compared to those of nerve growth factor (NGF, 50 ng/ml) which was used as a positive control. We evaluated several parameters of neurite outgrowth such as the neurite number, total neurite length and extend of branching. Our findings showed that GBE (10 and 100 μg/ml) significantly increased neurite outgrowth in the 2D as well as 3D culture model after 3 days of treatment with a comparable effect than that NGF. The use of the 3D cell culture allowed us to better reproduce the in vivo neuronal microenvironment for the evaluation the neurite formation after GBE treatment. In addition, we assessed the effects of GBE on the Akt/mTOR pathway, which is known to promote neuroplasticity induced by nerve growth factors. We showed that GBE treatment induced an increase of phosphorylated IGF1R (Tyr1135/Tyr1136), Akt (Ser473), TSC2 (Ser939), mTOR (Ser2448), PTEN (Ser380) and GSK3β (Ser9). Together, these findings indicate that GBE promotes neurite growth and activates the PI3K/Akt/mTOR pathway suggesting that this plant extract supports neuronal plasticity.
Sections du résumé
BACKGROUND
Standardized Ginkgo biloba extract (GBE) has demonstrated efficacy in the cognitive functional neuropsychiatric symptoms of patients with Alzheimer's disease (AD). With regard to its underlying molecular mode of action, first evidence was provided that GBE was able to modulate neuronal outgrowth in vitro, but the mechanisms underlying GBE effects on neuroplasticity remain unclear.
METHODOLOGY/PRINCIPAL FINDINGS
In this study, we investigated the effect of GBE on neurite outgrowth using SH-SY5Y neuroblastoma cells in a 2D and 3D surface culture. The effects of the GBE LI1370 on neuroplasticity and neurite outgrowth were compared to those of nerve growth factor (NGF, 50 ng/ml) which was used as a positive control. We evaluated several parameters of neurite outgrowth such as the neurite number, total neurite length and extend of branching. Our findings showed that GBE (10 and 100 μg/ml) significantly increased neurite outgrowth in the 2D as well as 3D culture model after 3 days of treatment with a comparable effect than that NGF. The use of the 3D cell culture allowed us to better reproduce the in vivo neuronal microenvironment for the evaluation the neurite formation after GBE treatment. In addition, we assessed the effects of GBE on the Akt/mTOR pathway, which is known to promote neuroplasticity induced by nerve growth factors. We showed that GBE treatment induced an increase of phosphorylated IGF1R (Tyr1135/Tyr1136), Akt (Ser473), TSC2 (Ser939), mTOR (Ser2448), PTEN (Ser380) and GSK3β (Ser9).
CONCLUSION
Together, these findings indicate that GBE promotes neurite growth and activates the PI3K/Akt/mTOR pathway suggesting that this plant extract supports neuronal plasticity.
Identifiants
pubmed: 31790465
doi: 10.1371/journal.pone.0225761
pii: PONE-D-19-18727
pmc: PMC6886765
doi:
Substances chimiques
Plant Extracts
0
Ginkgo biloba extract
19FUJ2C58T
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225761Déclaration de conflit d'intérêts
AE received study grants from Vifor Pharma Switzerland. Moreover AE and AG received lecturer/consultant fees from Vifor Pharma Switzerland. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
J Biol Chem. 1998 May 29;273(22):13375-8
pubmed: 9593664
Prog Neurobiol. 1998 Dec;56(5):541-69
pubmed: 9775403
Pharmacol Res. 2007 Dec;56(6):493-502
pubmed: 17977008
Int Psychogeriatr. 2012 Aug;24 Suppl 1:S18-20
pubmed: 22784423
FASEB J. 2007 Aug;21(10):2400-8
pubmed: 17356006
Neurochem Res. 2007 Apr-May;32(4-5):707-15
pubmed: 17024568
Exp Neurol. 2010 May;223(1):45-50
pubmed: 20079353
Evid Based Complement Alternat Med. 2012;2012:278273
pubmed: 22761636
Proc Natl Acad Sci U S A. 1976 Jul;73(7):2424-8
pubmed: 1065897
Evid Based Complement Alternat Med. 2013;2013:127075
pubmed: 23878590
World J Biol Psychiatry. 2019 Mar;20(3):173-189
pubmed: 28460580
Oxid Med Cell Longev. 2019 May 12;2019:9695412
pubmed: 31214285
J Comp Neurol. 2014 Aug 15;522(12):2741-55
pubmed: 24610700
Curr Alzheimer Res. 2018;15(1):89-99
pubmed: 28847282
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20057-62
pubmed: 19897719
Nature. 1987 Sep 3-9;329(6134):65-8
pubmed: 3627243
Brain Res Brain Res Rev. 1998 Jun;27(1):1-39
pubmed: 9639663
J Neurosci. 1986 Aug;6(8):2155-62
pubmed: 3746405
Eur J Neurosci. 2007 Nov;26(10):2931-9
pubmed: 18001288
Neurochem Int. 2015 Oct;89:126-39
pubmed: 26260546
Cell Mol Neurobiol. 2015 Aug;35(6):861-9
pubmed: 25822771
Neurobiol Dis. 2012 Apr;46(1):180-9
pubmed: 22297164
Neuropharmacology. 2010 May;58(6):911-20
pubmed: 19917299
Aging Dis. 2017 Dec 1;8(6):812-826
pubmed: 29344418
PLoS One. 2010 Aug 24;5(8):e12359
pubmed: 20808761
Biomed Pharmacother. 2018 Nov;107:329-337
pubmed: 30098550
Front Mol Neurosci. 2010 Feb 09;3:1
pubmed: 20162032
J Biol Chem. 2006 Aug 18;281(33):23785-91
pubmed: 16793764
ASN Neuro. 2010 Oct 04;2(5):e00045
pubmed: 20957078
Nat Cell Biol. 2002 Sep;4(9):648-57
pubmed: 12172553
Int Psychogeriatr. 2012 Aug;24 Suppl 1:S21-4
pubmed: 22784424
Cardiovasc Res. 2009 May 1;82(2):250-60
pubmed: 19147653
Mol Neurobiol. 2014 Apr;49(2):945-56
pubmed: 24154866
J Alzheimers Dis. 2009;18(4):787-98
pubmed: 19661619
J Neurochem. 2004 Sep;90(5):1144-55
pubmed: 15312169